BRITISH ASIANS have been warned to pay attention to their health by leading medical professionals, as a “diabetes epidemic” is predicted to trigger a rise in heart attack and strokes by 2035.
The number of people suffering from potentially fatal medical conditions due to diabetes is predicted to rise by 29 per cent, according to new analysis released by the British Heart Foundation (BHF) last month.
Moreover, despite advanced research techniques and developments in the field, it was announced that the diagnosis of all diabetes types in the UK has more than doubled in two decades.
According to Diabetes Research & Wellness Foundation (DRWF), the number stood at 1.8 million people over the age of 16 being diagnosed in 1998, compared to the most recent statistics which estimates over 3.8 million people having the condition.
This number is predicted to rise to five million over the next 20 years as the UK’s obesity rate increases.
The National Diabetes Audit from 2016-17 showed at least 8.4 per cent of patients with Type 1 and 19.3 per cent of patients with Type 2 are from an ethnic minority group.
Professor Sir Nilesh Samani, medical director at BHF, told Eastern Eye the knock-on effect of rising levels of health problems related to diabetes could be “massive”.
He added the increased risk of Asians developing the disease could be significant, causing future potential health problems.
“It is well known that obesity puts people at significant risk of developing diabetes… however, [it] is not the only contributing factor,” he said. “People with a family history of Type 2 diabetes are more at risk of developing the disease.
“And some ethnic groups have a much higher rate of diabetes – including people of south Asian origin.”
Samani also noted the risk of coronary heart disease (CHD) is up to 50 per cent higher in first-generation south Asians than in the white European population in the UK.
“We need more research to better understand why particular groups are at higher risk of diabetes, and to combat heart and circulatory diseases in people living with diabetes,” he said.
BHF has also addressed the strain the epidemic could have on health services. It expects the rise to put an “unprecedented” burden on the NHS, with previous estimates suggesting the yearly cost of treating individuals with diabetes will be £16.9 billion by 2035, up from £9.8bn in 2012.
Dr Kailash Chand, honorary vice president of the British Medical Association (BMA) and ex-chair of the NHS Trust, told Eastern Eye promoting knowledge about diet and exercise and taking responsibility for our lifestyle choices are the best ways to cut down on healthcare
costs and the strain on the NHS.
“Diabetes is a major public health problem that is approaching epidemic proportions globally,” he said. “A person with Type 2 diabetes is two-to-four times more likely to get cardiovascular disease, and 80 per cent of people with diabetes will die from it.”
Dr Chand, who has worked as a GP since 1983, advised members of the Asian community to focus on improving their diet, exercising regularly and attempting to reduce stress.
“[This advice] will not only boost quality of life but will curb the risk of death from cardiovascular disease and all causes,” he said.
Earlier this year, NHS figures confirmed Type 2 diabetes is closely associated with being very overweight.
Nearly four in five of the 715 children suffering with Type 2 diabetes in the UK were obese.
Almost half were black or Asian.
In June, the government released a childhood obesity report. It detailed strategies to tackle the issue, including having compulsory calorie counts on all menus in restaurants and takeaways; banning the sale of caffeine-filled energy drinks to children; limiting the number of unhealthy food adverts shown during children’s TV programmes and encouraging primary schools to introduce daily physical activities.
A senior cardiac nurse at BHF, Maureen Talbot, said although she believes the government are aware of the problem, they can always do more.
“We would like them to ensure the recommendations from the obesity plan are implemented in full,” she told Eastern Eye.
“The nature of eating habits as a child are the same habits you could take into adulthood. It is very important to ensure the habits of children are changed and their access to junk food isn’t as easy as it seems to be now.”
Talbot hopes the future generation will be educated on healthy lifestyle choices, to reduce the risk of diabetes numbers rising.
“No one wants to be a burden on the NHS or have a health condition, so having that awareness will hopefully happen in the next 20 years,” she said.
“School age children will hopefully learn about healthy eating, the importance of physical
activity, and how to maintain their health in adult life.”
Sonal Shah, a London-based nutritionist and director of Synergy Nutrition, told Eastern Eye that Asian communities need to be further educated on healthy eating.
“Their diets can be improved by watching portion sizes, reducing sugars from foods and drinks, and healthier cooking methods,” she advised. “Unhealthy habits that have been picked up just need to be swapped to healthier ones.”
Professor Jonathan Valabhji, national clinical director for diabetes and obesity at NHS England, referred to the BHF figures as “concerning”.
He added: “[This] underscores why we have been working hard to ensure England is the first country in the world to achieve full national coverage with an evidence-based Type 2 Diabetes Prevention Programme, for those at high risk of the disease.”
When contacted by Eastern Eye, a spokesperson for the department of health highlighted the new measures being taken to address the growing problem of obesity.
“Our new childhood obesity plan will get children exercising more in schools and reduce their exposure to sugary and fatty foods.
“This is in addition to the billions we have invested in public health services, and our reformulation efforts which have already removed the equivalent of 45 million kilograms of sugar from soft drinks every year.”
Shefali Jariwala died at 42 in Mumbai after reportedly collapsing post-fast; cause of death suspected to be cardiac arrest or blood pressure drop.
Police found anti-ageing pills, vitamin supplements, and glutathione injections at her residence.
Doctors stress the risks of unsupervised use of hormone-based and anti-ageing treatments.
Final post-mortem report expected in two days; no foul play suspected, case treated as accidental death.
The untimely death of actor-model Shefali Jariwala has sparked renewed concern over the unregulated use of anti-ageing treatments and self-medication. The 42-year-old, best known for her appearance in Kaanta Laga, was declared dead on arrival at a Mumbai hospital on Friday night. Initial investigations suggest she may have suffered a cardiac arrest following a steep drop in blood pressure, possibly linked to taking supplements on an empty stomach.
Shefali Jariwala death raises concern over anti ageing drugs and self medication Instagram/shefalijariwala
What caused Shefali Jariwala’s collapse? Police and doctors investigate
Shefali Jariwala was rushed to Bellevue Multispeciality Hospital by her husband and friends after she suddenly collapsed at home, but she was already unresponsive. Her family said she had been fasting for a religious ritual and had consumed her regular supplements shortly after breaking the fast. Among the substances recovered at her Andheri apartment were glutathione injections, commonly used for skin lightening, and various anti-ageing tablets.
Doctors at Cooper Hospital, where her post-mortem was conducted, suspect a fatal drop in blood pressure, though only the final autopsy will confirm the precise cause of death. So far, Mumbai Police have ruled out foul play and registered an accidental death report.
Health experts warn against unmonitored anti-ageing therapies
Experts are now urging caution over the growing trend of unsupervised beauty and anti-ageing regimens, especially among public figures. Dr Dhirendra Singhania, a leading cardiologist, pointed to steroids, hormone therapies, and poor sleep as major heart risk factors, even among seemingly fit individuals. While glutathione and vitamin C aren’t inherently dangerous, he said their misuse or interaction with other drugs can trigger complications.
Anti ageing pills found at Shefali Jariwala home spark health safety debate Instagram/shefalijariwala
Shefali had no known chronic illnesses apart from epilepsy, which doctors say is unlikely to be linked to her sudden collapse. Her death, while still under investigation, adds to growing concerns about beauty pressures, self-prescribed treatments, and the long-term risks of trying to defy ageing without medical oversight.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.
Prada acknowledges Indian influence behind its Spring Summer 2026 men’s footwear
• Prada confirms Indian roots behind 2026 ‘leather sandals’ after controversy • Indian artisans and officials accused the brand of cultural appropriation • The footwear resembles traditional Kolhapuri chappals with GI status • Prada says designs are still in development and open to dialogue with India
Italian fashion label Prada has officially acknowledged that its Spring/Summer 2026 menswear collection includes footwear inspired by India’s traditional Kolhapuri chappals. The statement came after mounting criticism from Indian artisans and industry leaders, who claimed the brand showcased the design at Milan Fashion Week without recognising its origins.
Prada confirms Kolhapuri chappals inspired its 2026 Milan collectionInstagram/prada
Prada responds to Kolhapuri chappal row
In a letter addressed to Lalit Gandhi, President of the Maharashtra Chamber of Commerce, Industry and Agriculture (MACCIA), Prada’s CSR head Lorenzo Bertelli confirmed the sandals were influenced by Indian craftsmanship. The fashion house admitted that the open-toe leather sandals presented on the Milan runway drew from the centuries-old Kolhapuri style, traditionally made by artisans in Maharashtra and Karnataka.
Kolhapuri chappals have been crafted for centuries and received GI tag in 2019 iStock
The controversy erupted after Prada described the footwear simply as “leather sandals” in its show notes, omitting any reference to India. This led to accusations of cultural appropriation and disregard for artisans' rights. BJP MP Dhananjay Mahadik also led a group of Kolhapuri chappal makers to meet Maharashtra Chief Minister Devendra Fadnavis, urging government action to protect their Geographical Indication (GI) status.
No production yet, says Prada, as India seeks fair credit
Prada clarified that the sandals shown were part of an early-stage design process and have not been confirmed for mass production. “None of the pieces are finalised or approved for commercial use,” Bertelli wrote.
MACCIA, in its communication, called for proper acknowledgement and possible collaboration or compensation for Indian artisans. The organisation stressed that Kolhapuri chappals are not just heritage products but also vital to the livelihoods of thousands of families.
In response, Bertelli assured Prada’s commitment to ethical design, cultural respect, and further engagement with Indian artisan communities. He also welcomed the opportunity for open dialogue on potential partnerships.
The Kolhapuri chappal, awarded GI status in 2019, is a symbol of regional identity and craftsmanship. As global fashion continues to borrow from traditional cultures, this case may set the tone for how brands address ownership, recognition, and respect.
Keep ReadingShow less
Wintour’s style of leadership earned her the nickname “Nuclear Wintour”
Anna Wintour steps down as editor of US Vogue after 37 years
She will remain Vogue’s global editorial director and hold senior roles at Condé Nast
Wintour transformed US Vogue into a global fashion authority
The 75-year-old has received numerous honours, including the Presidential Medal of Freedom
End of an era at US Vogue
Anna Wintour has stepped down as the editor of US Vogue, bringing to a close a 37-year tenure that redefined the publication and saw her become one of the most influential figures in global fashion.
The announcement was made on Thursday (26 June) during a staff meeting in New York. Wintour, 75, will no longer oversee the day-to-day editorial operations of Vogue’s US edition. However, she will continue to serve as Vogue’s global editorial director and Condé Nast’s chief content officer, maintaining senior leadership roles across the company.
A transformative legacy
Wintour took the helm of US Vogue in 1988, inheriting a relatively conservative magazine. She swiftly transformed it into a trendsetting, authoritative voice in fashion. Under her leadership, the publication became known for its iconic covers, high-end photography, and ability to shape careers in the fashion industry.
With extensive budgets and strong advertising support, Vogue became a global fashion flagship, influencing designers, celebrities, and brands worldwide.
Wintour’s style of leadership earned her the nickname “Nuclear Wintour” for her decisiveness, with some reports noting her tendency to make bold editorial decisions without extensive discussion. Her distinctive bob haircut and ever-present sunglasses made her a recognisable front-row figure at fashion weeks around the world.
Beyond the magazine
The British-born editor rose to wider public fame as the inspiration behind the character Miranda Priestly in The Devil Wears Prada — both the 2003 novel and the 2006 film adaptation. While Wintour rarely commented on the portrayal, she acknowledged the attention it brought, most recently during the launch of a stage musical adaptation in London in 2024.
She told the BBC, “They [my sunglasses] help me see and they help me not see. They help me be seen and not be seen. They are a prop, I would say.”
Wintour also became synonymous with the Met Gala, the annual high-profile charity event in New York City, which she has organised for years, drawing celebrities from fashion, film, politics, and sport.
Recognition and future plans
Wintour has received numerous accolades during her career. She was made a Dame Commander of the Order of the British Empire (DBE) in 2017 and became a Companion of Honour in February 2025. During the ceremony in London, she removed her sunglasses to receive the award and told King Charles III that she had no intention of retiring.
Wintour also became synonymous with the Met GalaGetty Images
In the United States, President Joe Biden awarded her the Presidential Medal of Freedom earlier this year before leaving office.
Despite stepping back from US Vogue, Wintour will continue to oversee several major Condé Nast titles including Wired, Vanity Fair, GQ, Condé Nast Traveler, and Glamour, as part of her global leadership responsibilities.
In her remarks to staff, she described the decision as “pivotal” but confirmed she would not be leaving the company or her office. “I’ll be turning all my attention to global leadership and working with our team of brilliant editors around the world,” she said.
Nadiya Hussain confirms BBC will not renew her cookery series
Bake Off winner challenges expectations to remain “grateful”
She says hard work and talent, not luck, brought her success
Celebrities, including Annie Lennox and Fearne Cotton, show support
BBC ends decade-long collaboration with Bake Off star
Nadiya Hussain has spoken out after the BBC decided not to commission another cookery programme with her. The popular TV chef, who won The Great British Bake Off in 2015, shared her views on social media, stating that she “won’t always be grateful” and should not be expected to remain silent about career setbacks.
The decision ends a nearly 10-year working relationship between the broadcaster and Hussain, who has hosted several well-received cookery shows under the BBC banner. In her latest Instagram video, she addressed the public’s reaction and emphasised her right to expect more from her career.
“Gratitude shouldn't be a muzzle”
In a video message posted on Instagram, Hussain said she had received numerous messages urging her to be grateful following the show's cancellation. She described how growing up in an immigrant household had shaped her understanding of gratitude.
“Grateful for being let in, grateful for having work—even if underpaid, grateful for safety—even if it meant silence,” she explained. “Gratitude became something that I was expected to wear like a uniform.”
She continued: “I am allowed to feel more than just thankful. I am a human being, and I am allowed to feel angry when I’m treated unfairly. I’m allowed to want better for myself and for my family.”
Challenging the idea that people from marginalised backgrounds must constantly express gratitude for any opportunities, she said: “We didn’t come here just to survive; we came here to live, to grow, to contribute, to belong—not as a guest, but as a person who has rights and dreams and dignity.”
Hussain concluded, “So no, I won’t always be grateful. I got here through hard work, through determination, through talent. I got here because I’m good at what I do.”
Nadiya’s message received widespread support from fans and fellow public figures. TV presenter Fearne Cotton responded with a series of heart emojis, while musician Annie Lennox praised her statement, writing: “Gratitude should never become a silencing muzzle—as you so rightly say!”
Rahul Mandal, who won Bake Off in 2018, commented: “So true. Thanks so much for speaking up.” TV doctor Amir Khan also backed her remarks, stating: “Exactly this! Well said.”
Nadiya’s track record with the BBC
Since winning Bake Off when it aired on the BBC, Hussain has fronted several successful cookery series for the broadcaster. These include Nadiya Bakes, Nadiya’s Fast Flavours, and Nadiya’s Simple Spices. She is also a published author of cookbooks and children’s titles.
Earlier this month, the BBC issued a statement on the programming decision: “After several wonderful series, we have made the difficult decision not to commission another cookery show with Nadiya Hussain at the moment.”
However, the broadcaster emphasised that it remains open to future collaborations and that Nadiya is “a much-valued part of the BBC family”.
What’s next for Nadiya?
While a new BBC project is not in the pipeline, Nadiya has hinted at future ventures. In a previous post addressing the show’s cancellation, she said she is now focusing on “being [her] most authentic self” and is looking forward to working with people who “believe in [her] talent”.
She also reassured her followers that “exciting” new projects are on the way.
Keep ReadingShow less
The importance of vigilance as demand for these weight loss and diabetes drugs continues to grow
Almost 400 reports of acute pancreatitis linked to weight loss and diabetes jabs have been filed in the UK
Most cases involve popular GLP-1 drugs including Ozempic, Wegovy, and Mounjaro
Health officials are investigating possible genetic causes behind the side-effects
Patients hospitalised with pancreatitis encouraged to report symptoms via MHRA’s Yellow Card scheme
Adverse drug reactions cost the NHS an estimated £2.2bn annually
Health watchdog investigates spike in serious side-effects from GLP-1 drugs
UK health authorities have launched a study into the side effects of popular weight loss and diabetes drugs following a spike in reported cases of acute pancreatitis. Nearly 400 reports have been received via the Medicines and Healthcare products Regulatory Agency’s (MHRA) Yellow Card scheme, which monitors side effects and adverse reactions related to medicines and medical devices.
The medicines involved are GLP-1 receptor agonists – including semaglutide (marketed as Ozempic and Wegovy), liraglutide, and tirzepatide (branded as Mounjaro). The Yellow Card data shows that 181 of the cases involved tirzepatide alone.
What is acute pancreatitis?
Acute pancreatitis is a sudden inflammation of the pancreas, the gland located behind the stomach that helps with digestion. Symptoms typically include severe abdominal pain, nausea, and fever, and the condition often requires hospital treatment. In rare cases, it can be fatal.
Though pancreatitis is listed as an “uncommon” side-effect of GLP-1 medications in patient information leaflets – meaning it may affect around one in 100 people – the MHRA has seen a notable rise in reported incidents, particularly in 2025.
Since the start of the year, there have been 22 reports involving semaglutide (Ozempic and Wegovy) and 101 involving tirzepatide (Mounjaro).
Study launched to explore potential genetic link
To understand the possible causes of these side effects, particularly in light of rising usage of these medications, the MHRA is inviting affected patients to take part in a research study through the Yellow Card Biobank. The initiative, run by Genomics England, will collect saliva samples and other data to explore any genetic factors that may be influencing patient response to GLP-1 drugs.
An MHRA spokesperson stated: “Alongside increased usage, we are seeing an upturn in the number of Yellow Card reports mentioning GLP-1 medicines and acute pancreatitis.”
While no known genetic link has yet been established, the MHRA said genetic variations could help explain why some patients experience adverse reactions to certain medications. The agency is urging both patients and health professionals to report suspected side-effects related to these drugs.
Adverse reactions place burden on NHS
Research shows that one in six hospital admissions is caused by an adverse drug reaction, and around a third of those could potentially be avoided through genetic testing. The financial cost is also significant – the NHS spends over £2.2 billion each year on hospital stays linked to adverse reactions alone.
Dr Alison Cave, chief safety officer at the MHRA, highlighted the need for more personalised approaches to medicine: “Evidence shows that almost a third of side-effects to medicines could be prevented with the introduction of genetic testing.”
Manufacturers respond to rising concerns
In response to the reports, drugmakers Lilly and Novo Nordisk reiterated their commitment to patient safety and advised that side effects should always be reported and discussed with healthcare professionals.
A spokesperson for Lilly, which manufactures Mounjaro, said: “Patient safety is Lilly’s top priority. We take reports seriously and actively monitor, evaluate and report safety information for all our medicines.”
The Mounjaro leaflet identifies acute pancreatitis as an uncommon side-effect, advising patients to consult their doctor before using the drug if they have a history of the condition.
Novo Nordisk UK, which produces Ozempic and Wegovy, issued a similar statement: “Patient safety is of the utmost importance to Novo Nordisk… The known risks and benefits of GLP-1 medicines are described in the product information. We recommend that patients take these medications only for their approved indications and under the strict supervision of a healthcare professional.”
Both companies said they were continuously collecting safety data and working with authorities to ensure ongoing monitoring and understanding of their treatments.
What should patients do?
Health officials are encouraging patients who have experienced severe symptoms such as abdominal pain, nausea, or fever after taking these medications to report their experiences to the Yellow Card scheme. Hospitalised individuals may be contacted to participate in the Biobank study.
While the overall safety profile of GLP-1 medicines remains positive, the MHRA has stressed the importance of vigilance as demand for these weight loss and diabetes drugs continues to grow.